Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

67.12USD
9:51am EDT
Change (% chg)

$0.62 (+0.94%)
Prev Close
$66.50
Open
$66.75
Day's High
$67.25
Day's Low
$66.37
Volume
615,038
Avg. Vol
7,165,216
52-wk High
$79.61
52-wk Low
$60.32

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

  GILD.O Industry Sector
P/E (TTM): 8.92 69.30 32.55
EPS (TTM): 9.21 -- --
ROI: 27.00 8.91 13.82
ROE: 63.92 10.05 15.24

Gilead to separate Kite cell therapy unit, posts higher profit

Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.

May 02 2019

UPDATE 1-Gilead to separate Kite cell therapy unit, posts higher profit

May 2 Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.

May 02 2019

Gilead posts higher first-quarter profit; drug sales in line with expectations

May 2 Gilead Sciences Inc on Thursday reported a higher first-quarter profit as sales of its important HIV and hepatitis C drugs were largely in line with Wall Street estimates.

May 02 2019

Gilead experimental NASH drug fails another study

Gilead Sciences Inc's experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study on Thursday, two months after it failed another trial.

Apr 25 2019

REFILE-UPDATE 2-Gilead experimental NASH drug fails another study

April 25 Gilead Sciences Inc's experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study on Thursday, two months after it failed another trial.

Apr 25 2019

Gilead's NASH drug fails to meet late-stage study goal

April 25 Gilead Sciences Inc said on Thursday its experimental drug to treat scarring of tissue due to nonalcoholic steatohepatitis (NASH) did not meet main goal of a late stage trial.

Apr 25 2019

Gilead teams up with insitro for experimental NASH treatments

Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.

Apr 16 2019

Gilead teams up with insitro for experimental NASH treatments

April 16 Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.

Apr 16 2019

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Apr 12 2019

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN, April 12 Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Apr 12 2019

Earnings vs. Estimates